Valbenazine granted breakthrough drug status for treating tardive dyskinesia

Müller, Thomas

doi:10.1517/13543784.2015.1029573

Cited by 42 publications

(33 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VMAT2 inhibitors, such as tetrabenazine, which act primarily by depleting presynaptic dopamine rather than by blocking postsynaptic dopamine receptors, have not been documented to cause TD 26. Indeed, tetrabenazine and novel VMAT2 inhibitors, such as deutetrabenazine and NBI-98854,27,28 are currently under clinical investigation for the treatment of TD.…”

Section: Discussionmentioning

confidence: 99%

Deutetrabenazine in Tics Associated with Tourette Syndrome

Jankovic

Jimenez‐Shahed

Budman

et al. 2016

Tremor and Other Hyperkinetic Movements

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Deutetrabenazine in Tics Associated with Tourette Syndrome

Jankovic

Jimenez‐Shahed

Budman

et al. 2016

Tremor and Other Hyperkinetic Movements

View full text Add to dashboard Cite

“…However, valbenazine appears to have fewer side effects and a more favorable once-daily dosing regimen for the treatment of TD. Tardive dyskinesia (TD) is an involuntary movement disorder induced by prolonged exposure to dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics [1,2]. Research shows that the prescription of antipsychotics alone increased more than threefold over 10 years; conservative estimates thus indicate that approximately 5 million patients have been exposed to antipsychotics in the United States (US) [3].…”

mentioning

confidence: 99%

“…Recognizing that TD was an important unmet medical need and that a proven TD treatment would be an important pharmacological development, the US FDA granted breakthrough status to valbenazine in 2015 and approval as a treatment for TD in 2017 [2,25]. Valbenazine is a novel and highly selective VMAT2 inhibitor that is rapidly absorbed but more slowly metabolized, with a half-life of approximately 20 h that supports oncedaily dosing [22,26].…”

mentioning

confidence: 99%

Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review

2018

View full text Add to dashboard Cite

Up to 30% of patients taking antipsychotics may develop tardive dyskinesia (TD). Recent evidence-based recommendations demonstrate an unmet need for effective TD management. This systematic review was designed to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, tetrabenazine and valbenazine. Of 487 PubMed/Embase search results, 11 studies met the review criteria. Valbenazine efficacy was demonstrated in rigorously designed clinical trials that meet the guidelines for AAN Class I evidence. Due to differences in study designs and a lack of standardized and controlled trials with tetrabenazine, a formal meta-analysis comparing the agents was not possible. However, valbenazine appears to have fewer side effects and a more favorable once-daily dosing regimen for the treatment of TD. Tardive dyskinesia (TD) is an involuntary movement disorder induced by prolonged exposure to dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics [1,2]. Research shows that the prescription of antipsychotics alone increased more than threefold over 10 years; conservative estimates thus indicate that approximately 5 million patients have been exposed to antipsychotics in the United States (US) [3]. Given that the estimated global mean prevalence of TD is 30% in studies of patients currently treated with a first-generation antipsychotic and 21% in those currently treated with a second-generation antipsychotic, this disorder remains a significant problem for psychiatric patients who may experience stigma, embarrassment, and impairment in social functioning (and sometimes physical functioning) as a consequence of developing TD [4]. While the prevalence of TD has been extensively studied, the associated healthcare burden is the subject of continuing investigation [3][4][5]. Previous studies have shown that the presence of TD in patients with schizophrenia may correlate with impaired cognition, poor response to treatment, greater risk of relapse, longer hospital stays, lower quality of life and functioning, a progressive course, and increased mortality [6].Through the mechanism of blocking dopamine receptors, antipsychotics have proven to be highly effective and essential drugs for controlling psychotic symptoms in patients with conditions such as schizophrenia and bipolar disorder [7][8][9][10]. However, dopamine is also involved as a key neurotransmitter in other neural pathways, notably the motor circuit [7,11]. Blockade in the motor circuit may lead to upregulation and hypersensitivity of post-synaptic dopamine receptors, resulting in an increase of dopaminergic signaling and the emergence of abnormal movements associated with TD [10,12].Vesicular monoamine transporters (VMATs) are presynaptic intracellular transmembrane proteins that have a critical role in the packaging, storage and release of dopamine and other monoamines [13]. Inhibition of VMAT2, which is the predominant isoform in the brain, interferes with dopamine uptake and storage in presynapti...

show abstract

“…Erkenntnisse aus der arti ziellen Studienwelt sind dazu nicht geeignet [1,2]. Da Valbenazin nicht zu β-Dihydrotetrabenazinderivaten metabolisiert wird [3], stellt sich die Frage, ob Valbenazin nicht langfristig die bessere Alternative zu SD809 ist.…”

unclassified

Deuteriertes Tetrabenazin verringert unkontrollierte Bewegungen

Müller

2017

InFo Neurologie

Self Cite

View full text Add to dashboard Cite

Valbenazine granted breakthrough drug status for treating tardive dyskinesia

Cited by 42 publications

References 30 publications

Deutetrabenazine in Tics Associated with Tourette Syndrome

Deutetrabenazine in Tics Associated with Tourette Syndrome

Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review

Deuteriertes Tetrabenazin verringert unkontrollierte Bewegungen

Contact Info

Product

Resources

About